| Hypothalamic hormones and cancer AV Schally, AM Comaru-Schally, A Nagy, M Kovacs, K Szepeshazi, ... Frontiers in neuroendocrinology 22 (4), 248-291, 2001 | 394 | 2001 |
| The role of indoleamine-2, 3-dioxygenase in cancer development, diagnostics, and therapy L Hornyák, N Dobos, G Koncz, Z Karányi, D Páll, Z Szabó, G Halmos, ... Frontiers in immunology 9, 151, 2018 | 330 | 2018 |
| Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. A Nagy, AV Schally, P Armatis, K Szepeshazi, G Halmos, M Kovacs, ... Proceedings of the National Academy of Sciences 93 (14), 7269-7273, 1996 | 273 | 1996 |
| Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers B Sun, G Halmos, AV Schally, X Wang, M Martinez The Prostate 42 (4), 295-303, 2000 | 224 | 2000 |
| Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers Z Rekasi, T Czompoly, AV Schally, G Halmos Proceedings of the National Academy of Sciences 97 (19), 10561-10566, 2000 | 215 | 2000 |
| High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers G Halmos, JM Arencibia, AV Schally, R Davis, DG Bostwick The Journal of urology 163 (2), 623-629, 2000 | 213 | 2000 |
| Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin A Nagy, AV Schally, G Halmos, P Armatis, RZ Cai, V Csernus, M Kovács, ... Proceedings of the National Academy of Sciences 95 (4), 1794-1799, 1998 | 206 | 1998 |
| Peptide analogs in the therapy of prostate cancer AV Schally, AM Comaru‐Schally, A Plonowski, A Nagy, G Halmos, ... The prostate 45 (2), 158-166, 2000 | 185 | 2000 |
| Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression G Halmos, JL Wittliff, AV Schally Cancer research 55 (2), 280-287, 1995 | 159 | 1995 |
| PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? ML Gasparri, E Bardhi, I Ruscito, A Papadia, AA Farooqi, C Marchetti, ... Geburtshilfe und Frauenheilkunde 77 (10), 1095-1103, 2017 | 151 | 2017 |
| The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues A Havt, AV Schally, G Halmos, JL Varga, GL Toller, JE Horvath, ... Proceedings of the National Academy of Sciences 102 (48), 17424-17429, 2005 | 148 | 2005 |
| Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2 … A Nagy, P Armatis, RZ Cai, K Szepeshazi, G Halmos, AV Schally Proceedings of the National Academy of Sciences 94 (2), 652-656, 1997 | 122 | 1997 |
| Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro Y Qin, T Ertl, RZ Cai, G Halmos, AV Schally Cancer research 54 (4), 1035-1041, 1994 | 121 | 1994 |
| Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II … A Jungwirth, J Pinski, G Galvan, G Halmos, K Szepeshazi, RZ Gai, ... European Journal of Cancer 33 (7), 1141-1148, 1997 | 120 | 1997 |
| Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. M Zarandi, JE Horvath, G Halmos, J Pinski, A Nagy, K Groot, Z Rekasi, ... Proceedings of the National Academy of Sciences 91 (25), 12298-12302, 1994 | 117 | 1994 |
| Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. G Halmos, AV Schally, J Pinski, M Vadillo-Buenfil, K Groot Proceedings of the National Academy of Sciences 93 (6), 2398-2402, 1996 | 116 | 1996 |
| Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. T Yano, J Pinski, G Halmos, K Szepeshazi, K Groot, AV Schally Proceedings of the National Academy of Sciences 91 (15), 7090-7094, 1994 | 111 | 1994 |
| Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin … J Pinski, G Halmos, T Yano, K Szepeshazi, Y Qin, T Ertl, AV Schally International journal of cancer 57 (4), 574-580, 1994 | 111 | 1994 |
| Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities JL Varga, AV Schally, VJ Csernus, M Zarándi, G Halmos, K Groot, ... Proceedings of the National Academy of Sciences 96 (2), 692-697, 1999 | 110 | 1999 |
| RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases L Halász, Z Karányi, B Boros-Oláh, T Kuik-Rózsa, É Sipos, É Nagy, ... Genome research 27 (6), 1063-1073, 2017 | 106 | 2017 |